Company performance
Current Price
as of Jun 11, 2025$8.15
P/E Ratio
N/A
Market Cap
$564.26M
Description
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerRGLS
- Price$8.15-1.81%
Trading Information
- Market cap$564.26M
- Float82.80%
- Average Daily Volume (1m)1,118,347
- Average Daily Volume (3m)2,091,636
- EPS-$0.73
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$9.63M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$10.45M
- EV$52.37M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B7.83
- Debt/Equity2.88